Objective The goal of the PEACHI project is to develop simple, affordable and effective vaccine strategies that can be given alone or in combination to prevent hepatitis C virus (HCV), human immunodeficiency virus type 1 (HIV-1) and co-infection. The vaccines are based on novel and powerful viral vectors for in vivo delivery of antigens.The PEACHI Consortium members have employed replication-defective simian adenovirus (ChAd) and modified vaccinia virus Ankara (MVA) vector technology to develop the most immunogenic HCV and HIV-1 vaccines to date. We will assess the safety and immunogenicity of ChAd prime / MVA boost HCV vaccines in a key target group - HIV-positive individuals receiving antiretroviral therapy. These data are essential to support future efficacy studies aiming to assess protection of HIV-infected people from HCV infection. In addition, we will conduct the first phase I clinical studies using two distinct ChAd vectors simultaneously, one hosting an HCV immunogen spanning the entire NS region of HCV and the other, highly conserved HIV-1 sequences. This strategy aims to prime responses against both HCV and HIV-1 antigenic targets concurrently. Similarly, responses will be boosted simultaneously, using MVA vectors that host the respective HIV-1 and HCV immunogens. Finally, recent work by Consortium members has shown that the immunogenicity of ChAd and MVA vectors is markedly improved when the encoded HCV immunogen is fused to mouse or human MHC class II invariant chain. This may be critical to the effectiveness of HCV vaccines in HIV-infected people and will be applicable to vaccine development for other major infectious diseases. Therefore, a large component of this project will be the first assessment of this novel technology in humans. Clinical studies will be complemented by comprehensive laboratory analyses to assess the strength and quality of vaccine-induced T cell responses using state-of-art assays, which will facilitate the discovery of surrogate markers of protective immunity. Fields of science natural sciencesbiological sciencesmicrobiologyvirologymedical and health scienceshealth sciencesinfectious diseasesRNA viruseshepatitis Cmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccinesnatural sciencesmathematicspure mathematicsarithmeticsprime numbers Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Topic(s) HEALTH.2012.2.3.2-1 - Co-infection of HIV/AIDS, malaria, tuberculosis and/or hepatitis Call for proposal FP7-HEALTH-2012-INNOVATION-1 See other projects for this call Funding Scheme CP-FP - Small or medium-scale focused research project Coordinator THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Address Wellington square university offices OX1 2JD Oxford United Kingdom See on map Region South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire Activity type Higher or Secondary Education Establishments Administrative Contact Gill Wells (Ms.) Links Contact the organisation Opens in new window Website Opens in new window EU contribution No data Participants (4) Sort alphabetically Sort by EU Contribution Expand all Collapse all REITHERA SRL Italy EU contribution € 1 645 648,00 Address Via di castel romano 100 00128 Roma See on map Region Centro (IT) Lazio Roma Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Antonella Folgori (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Other funding No data BORD OSPIDEIL NAOIMH SHEAMUIS Ireland EU contribution € 480 580,00 Address James s street 8 Dublin See on map Activity type Research Organisations Administrative Contact Colm Bergin (Prof.) Links Contact the organisation Opens in new window Website Opens in new window Other funding No data KANTONSSPITAL ST. GALLEN Switzerland EU contribution € 562 300,00 Address Rorschacherstrasse 95 9007 St. gallen See on map Region Schweiz/Suisse/Svizzera Ostschweiz St. Gallen Activity type Research Organisations Administrative Contact Pietro Vernazza (Prof.) Links Contact the organisation Opens in new window Website Opens in new window Other funding No data GLAXOSMITHKLINE BIOLOGICALS SA Belgium EU contribution € 0,00 Address Rue de l institut 89 1330 Rixensart See on map Region Région wallonne Prov. Brabant Wallon Arr. Nivelles Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Philippe Denoel (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Other funding No data
